Onward Medical N.V. (ONWD) Earnings Call Transcripts

Onward Medical N.V.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Onward Medical N.V. reported revenues of EUR 2 million, driven by strong commercial traction of the ARC-EX system, which generated EUR 1.3 million from product sales. The company raised EUR 40 million in equity financing, extending its cash runway into Q1 2028, which is a significant positive for operational stability. Management maintained a positive outlook, highlighting ongoing clinical trials and expanding market presence, particularly in the U.S. Veteran Affairs Administration, which could further enhance sales in the coming quarters.

Reported metrics

Guidance from management

Management expects continued commercial traction and plans to announce further clinical milestones, including interim results from the Empower BP study within the next year. They aim to convert a high percentage of VA evaluations into sales in upcoming quarters.

What management said

Thanks, Dave. Next slide. Revenue for the quarter was EUR 2 million, of which $1.3 million of that was product and revenue sales. As you've heard from Dave, our -- we strengthened our balance sheet right after the end of the quarter. So -- at the end of Q1, our cash available was EUR 53.4 million post the raise of capital in early April, our cash balance at the end of April was EUR 89.8 million, which allows us to ex...

Sure, Dave. The progress in the VA has been really fantastic. The VA is truly a notoriously challenging institution with a lot of of highly regional and kind of localized policies instead of kind of 1 set of governance that governs the entire country. There are 25 hubs. So the for spinal cord care works on a hub-and-spoke model. There are 25 hubs. We're in approximately half of those with many of those that we're now...

What analysts pressed on

Analysts expressed concerns regarding the conversion rate of VA evaluations into actual sales, given the lengthy evaluation process. There were also questions about the granularity of sales data across different categories, which management did not provide.

Main topics on the call

• Revenue Growth from ARC-EX — Onward Medical achieved EUR 2 million in total revenue for Q1, with EUR 1.3 million attributed to product sales from ARC-EX. Management noted, "we continue to see accelerating demand," indicating strong market interest a...
• Successful Equity Financing — The company raised over EUR 40 million, including EUR 25 million from EQT Life Sciences, which strengthens its balance sheet significantly. CEO David Marver stated, "our cash runway now extends into Q1 2028," providing a...
• Expansion into Home Use Market — Onward Medical has begun offering ARC-EX technology for home use, which is expected to expand their market significantly. Management highlighted that they sold more personal units than clinic units in Q1, a trend they ex...
• Progress in Clinical Trials — The company enrolled the first participant in the Empower BP pivotal trial and activated 12 sites in the U.S. for this study. This is a critical step towards regulatory approval for blood pressure instability, which mana...

Read the full Onward Medical N.V. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Onward Medical N.V. earnings call transcripts on record, spanning November 26, 2024 to May 26, 2026. Based on this history, Onward Medical N.V. reports quarterly. The most recent call on file is dated May 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ONWD

Exchange

ENXTBR

Country

BE

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

6

First call

November 26, 2024

Most recent

May 26, 2026

Reporting cadence

quarterly